Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative ef...

por Sklarz, L.-M., Gladbach, Y. S., Ernst, M., Hamed, M., Roolf, C., Sender, S., Beck, J., Schütz, E., Fischer, S., Struckmann, S., Junghanss, C., Fuellen, G., Murua Escobar, H.
Publicado 2020